Skip to main content

Wegovy Dosage

Generic name: SEMAGLUTIDE 0.25mg in 0.5mL
Dosage form: injection, solution
Drug class: Incretin mimetics

Medically reviewed by Last updated on Jun 4, 2021.

Patient Selection

Select patients for WEGOVY treatment as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management based on their BMI. BMI is calculated by dividing weight (in kilograms) by height (in meters) squared. A chart for determining BMI based on height and weight is provided in Table 1.

Table 1. BMI Conversion Chart
Table 1

Important Administration Instructions

Prior to initiation of WEGOVY, train patients on proper injection technique. Refer to the accompanying Instructions for Use for complete administration instructions with illustrations.
Inspect WEGOVY visually prior to each injection. Only use if solution is clear, colorless, and contains no particles.
Administer WEGOVY once weekly, on the same day each week, at any time of day, with or without meals.
Administer WEGOVY subcutaneously in the abdomen, thigh, or upper arm. The time of day and the injection site can be changed without dose adjustment.
If one dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY as soon as possible. If one dose is missed and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose. Resume dosing on the regularly scheduled day of the week.
If more than 2 consecutive doses are missed, resume dosing as scheduled or, if needed, reinitiate WEGOVY and follow the dose escalation schedule, which may reduce the occurrence of gastrointestinal symptoms associated with reinitiation of treatment.

Recommended Dosage

Initiate WEGOVY with a dose of 0.25 mg injected subcutaneously once-weekly and follow the dose escalation schedule in Table 2 to minimize gastrointestinal adverse reactions [see Adverse Reactions (6.1)].

Table 2. Dose Escalation Schedule


Weekly Dose

1 through 4

0.25 mg

Dose escalation

5 through 8

0.5 mg

9 through 12

1 mg

13 through 16

1.7 mg

Week 17 and onward

2.4 mg

Maintenance dose

If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks.
The maintenance dose of WEGOVY is 2.4 mg injected subcutaneously once-weekly.
If patients do not tolerate the maintenance 2.4 mg once-weekly dose, the dose can be temporarily decreased to 1.7 mg once-weekly, for a maximum of 4 weeks. After 4 weeks, increase WEGOVY to the maintenance 2.4 mg once-weekly. Discontinue WEGOVY if the patient cannot tolerate the 2.4 mg dose.
In patients with type 2 diabetes, monitor blood glucose prior to starting WEGOVY and during WEGOVY treatment.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.